Dichloroacetate, an inhibitor of pyruvate dehydrogenase kinases, inhibits platelet aggregation and arterial thrombosis
- 14 August 2018
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 2 (15) , 2029-2038
Abstract
Resting platelets rely on oxidative phosphorylation (OXPHOS) and aerobic glycolysis (conversion of glucose to lactate in the presence of oxygen) to generate adenosine triphosphate, whereas activated platelets exhibit a high level of aerobic glycolysis, suggesting the existence of metabolic flexibility in platelets. Mitochondrial pyruvate dehydrogenase kinases (PDK 1-4) play a pivotal role in metabolic flexibility by inhibiting pyruvate dehydrogenase complex. We determined whether metabolic reprogramming, diverting metabolism from aerobic glycolysis back to OXPHOS, would inhibit platelet function. PDKs activity in human and mouse platelets was inhibited with dichloroacetic acid (DCA), a potent inhibitor of all 4 forms of PDK. Human and mouse platelets pretreated with DCA exhibited decreased platelet aggregation to suboptimal doses of collagen, convulxin, thrombin, and adenosine diphosphate concomitant with decreased glucose uptake. Bioenergetics profile revealed that platelets pretreated with DCA exhibited decreased aerobic glycolysis in response to convulxin only. Furthermore, DCA inhibited ATP secretion, thromboxane A2 generation, and tyrosine phosphorylation of Syk and PLCγ2 in response to collagen or convulxin in human and mouse platelets (P < .05 vs vehicle treated). In the flow chamber assay, human and mouse blood pretreated with DCA formed smaller thrombi when perfused over collagen for 10 minutes at an arterial shear rate of 1500 s−1 (P < .05 vs control). Wild-type mice pretreated with DCA were less susceptible to thrombosis in the FeCl3-induced carotid and laser injury–induced mesenteric artery thrombosis models (P < .05 vs vehicle control), without altering hemostasis. Targeting metabolic plasticity with DCA may be explored as a novel strategy to inhibit platelet function. Key Points DCA, an inhibitor of PDKs, impedes glucose uptake and aerobic glycolysis in activated platelets. DCA inhibits agonist-induced human and mouse platelet aggregation and arterial thrombosis without altering hemostasis in mice. Visual AbstractKeywords
This publication has 28 references indexed in Scilit:
- Methods for defining distinct bioenergetic profiles in platelets, lymphocytes, monocytes, and neutrophils, and the oxidative burst from human bloodLaboratory Investigation, 2013
- Novel Antiplatelet Drug Revacept (Dimeric Glycoprotein VI-Fc) Specifically and Efficiently Inhibited Collagen-Induced Platelet Aggregation Without Affecting General Hemostasis in HumansCirculation, 2011
- Contribution of the P2Y12 receptor‐mediated pathway to platelet hyperreactivity in hypercholesterolemiaJournal of Thrombosis and Haemostasis, 2011
- Dichloroacetate induces apoptosis and cell-cycle arrest in colorectal cancer cellsBritish Journal of Cancer, 2010
- Monitoring phosphorylation of the pyruvate dehydrogenase complexAnalytical Biochemistry, 2009
- Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancerBritish Journal of Cancer, 2008
- Cooperation and Competition in the Evolution of ATP-Producing PathwaysScience, 2001
- Treatment of Lactic Acidosis with DichloroacetateNew England Journal of Medicine, 1983
- Metabolic Effects of Dichloroacetate in Patients with Diabetes Mellitus and HyperlipoproteinemiaNew England Journal of Medicine, 1978
- Studies on Human Platelet Glycolysis. Effect of Glucose, Cyanide, Insulin, Citrate, and Agglutination and Contraction on Platelet Glycolysis*Journal of Clinical Investigation, 1967